LY6D is a marker of urothelial and squamous differentiation and the extended validation in the present study supports its potential clinical utility as a complementary diagnostic and prognostic biomarker for improved clinical management of patients with bladder cancer, given that the presence of variant histology is taken into account. The gene discussed is LY6D; the disease is urinary bladder cancer.